213 related articles for article (PubMed ID: 37572198)
1. Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Nishiyama H; Inoue T; Koizumi Y; Kobayashi Y; Kitamura H; Yamamoto K; Takeda T; Yamamoto T; Yamamoto R; Matsubara T; Hoshino J; Yanagita M;
Int J Clin Oncol; 2023 Oct; 28(10):1298-1314. PubMed ID: 37572198
[TBL] [Abstract][Full Text] [Related]
2. [Precautions during Cancer Drug Therapy for CKD, Dialysis, and Renal Transplant Patients].
Koizumi Y
Gan To Kagaku Ryoho; 2022 Nov; 49(11):1195-1199. PubMed ID: 36412019
[TBL] [Abstract][Full Text] [Related]
3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
4. Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Muto S; Matsubara T; Inoue T; Kitamura H; Yamamoto K; Ishii T; Yazawa M; Yamamoto R; Okada N; Mori K; Yamada H; Kuwabara T; Yonezawa A; Fujimaru T; Kawano H; Yokoi H; Doi K; Hoshino J; Yanagita M
Int J Clin Oncol; 2023 Oct; 28(10):1259-1297. PubMed ID: 37382749
[TBL] [Abstract][Full Text] [Related]
5. [Management of chemotherapy in hemodialysis patients].
Janus N; Launay-Vacher V; Deray G; Thyss A; Thariat J
Bull Cancer; 2012 Mar; 99(3):371-80. PubMed ID: 22133734
[TBL] [Abstract][Full Text] [Related]
6. Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants.
Casal MA; Ivy SP; Beumer JH; Nolin TD
Lancet Oncol; 2021 Sep; 22(9):1333-1340. PubMed ID: 34399096
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report.
Hirakawa H; Nakashima C; Nakamura T; Masuda M; Funakoshi T; Nakagawa S; Horimatsu T; Matsubara K; Muto M; Kimura S; Sueoka-Aragane N
J Med Case Rep; 2017 Feb; 11(1):43. PubMed ID: 28202048
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.
Velenosi TJ; Urquhart BL
Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1131-43. PubMed ID: 24961255
[TBL] [Abstract][Full Text] [Related]
9. Society for Maternal-Fetal Medicine Consult Series #66: Prepregnancy evaluation and pregnancy management of patients with solid organ transplants.
; Irani RA; Coscia LA; Chang E; Lappen JR;
Am J Obstet Gynecol; 2023 Aug; 229(2):B10-B32. PubMed ID: 37088276
[TBL] [Abstract][Full Text] [Related]
10. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
Abe M; Okada K; Soma M
Curr Drug Metab; 2011 Jan; 12(1):57-69. PubMed ID: 21303332
[TBL] [Abstract][Full Text] [Related]
11. A quantitative approach to drug dosing in chronic kidney disease.
Olyaei AJ; Steffl JL
Blood Purif; 2011; 31(1-3):138-45. PubMed ID: 21228582
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and dosage adjustment in patients with renal dysfunction.
Verbeeck RK; Musuamba FT
Eur J Clin Pharmacol; 2009 Aug; 65(8):757-73. PubMed ID: 19543887
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous chemoradiation with cisplatin in a patient with recurrent cervical cancer undergoing hemodialysis: analysis of cisplatin concentrations in serum and dialysate and therapy-related acute toxicity.
Marnitz S; Kettritz R; Kahl A; Lehenbauer-Dehm S; Förster L; Budach V; Köhler C
Strahlenther Onkol; 2011 Dec; 187(12):831-4. PubMed ID: 22127362
[TBL] [Abstract][Full Text] [Related]
14. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.
Kintzel PE; Dorr RT
Cancer Treat Rev; 1995 Jan; 21(1):33-64. PubMed ID: 7859226
[TBL] [Abstract][Full Text] [Related]
15. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression?
Malyszko J; Glowinska I; Mysliwiec M
Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic Dosing in Chronic Kidney Disease and End-Stage Renal Disease: A Focus on Contemporary Challenges.
Vilay AM
Adv Chronic Kidney Dis; 2019 Jan; 26(1):61-71. PubMed ID: 30876619
[TBL] [Abstract][Full Text] [Related]
17. Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastoma.
Boucher AA; Mizuno T; Vinks AA; Goldstein SL; Tiao GM; Geller JI
Pediatr Blood Cancer; 2019 Jan; 66(1):e27425. PubMed ID: 30160353
[TBL] [Abstract][Full Text] [Related]
18. Recovery of Renal Function in a Kidney Transplant Patient After Receiving Hemodialysis for 4 Months.
Tsai JL; Tsai SF
Exp Clin Transplant; 2020 Feb; 18(1):112-115. PubMed ID: 30066627
[TBL] [Abstract][Full Text] [Related]
19. [REIN Report 2011--summary].
Couchoud C; Lassalle M; Jacquelinet C
Nephrol Ther; 2013 Sep; 9 Suppl 1():S3-6. PubMed ID: 24119584
[TBL] [Abstract][Full Text] [Related]
20. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster AC; Wu S; Tallapragada K; Park MY; Chapman JR; Carr SJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD004756. PubMed ID: 28731207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
